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Abstract
Rationale: Adiponectin is an anti-inflammatory adipokine that is the most abundant gene product of adipose tissue. Lower
levels have been observed in obesity, insulin resistance, and in critical illness. However, elevated levels early in acute
respiratory failure have been associated with mortality. Polymorphisms in adiponectin-related genes (ADIPOQ, ADIPOR1,
ADIPOR2) have been examined for relationships with obesity, insulin resistance and diabetes, cardiovascular disease, and to
circulating adipokine levels, but many gaps in knowledge remain. The current study aims to assess the association between
potentially functional polymorphisms in adiponectin-related genes with acute respiratory distress syndrome (ARDS) risk and
mortality.
Methods: Consecutive patients with risk factors for ARDS admitted to the ICU were enrolled and followed prospectively for
development of ARDS. ARDS cases were followed through day 60 for all-cause mortality. 2067 patients were successfully
genotyped using the Illumina CVD BeadChip high-density platform. Of these, 567 patients developed ARDS. Forty-four
single nucleotide polymorphisms (SNPs) on ADIPOQ, ADIPOR1 and ADIPOR2 were successfully genotyped. Of these, 9 SNPs
were hypothesized to be functional based on their location (promoter, exon, or 39 untranslated region). These 9 SNPs were
analyzed for association with ARDS case status and mortality among ARDS cases.
Results: After multivariable analysis and adjustment for multiple comparisons, no SNPs were significantly associated with
ARDS case status. Among ARDS cases, homozygotes for the minor allele of rs2082940 (ADIPOQ) had increased mortality
(hazard ratio 2.61, 95% confidence interval 1.36–5.00, p= 0.0039) after adjustment for significant covariates. The significance
of this association persisted after adjustment for multiple comparisons (FDR_q= 0.029).
Conclusions: A common and potentially functional polymorphism in ADIPOQ may impact survival in ARDS. Further studies
are required to replicate these results and to correlate genotype with circulating adiponectin levels.
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Introduction
Adipose tissue is now recognized as an active endocrine organ.
Adipocytes, the primary cells making up adipose, secrete
adipokines that have been studied as phenotypic markers for
obesity. Adipokines are involved in vascular and generalized
inflammation, as well as insulin resistance and atherogenesis [1–5].
They have also been studied in animal models of sepsis [6,7].
Adiponectin is an anti-inflammatory, anti-diabetic, and anti-
atherogenic adipokine that is the most abundant gene product of
adipose tissue [1–4,8]. Adiponectin is encoded by ADIPOQ,
located on chr3q27. Adiponectin binds to the AdipoR1 and
AdipoR2 receptors, encoded by ADIPOR1 (chr1q32) and ADI-
POR2 (chr12p13) respectively. AdipoR1 is ubiquitously expressed,
particularly in skeletal muscle, while AdipoR2 is primarily
expressed in liver as well as skeletal muscle [9,10]. These receptors
mediate the biologic effects of adiponectin, and they have strong
similarities to G-protein-coupled receptors although they are
distinct from this class of receptors. Binding of adiponectin to its
receptors results in activation of unique signaling molecules such as
AMPK, p38 MAPK, and PPAR-a [10].
Adiponectin has been studied widely in obesity and diabetes,
and it is a key suppressor of the metabolic derangements leading to
insulin resistance, type 2 diabetes mellitus, metabolic syndrome,
and cardiovascular disease [11]. For instance, lower plasma levels
of plasma adiponectin have been observed in obesity, insulin
resistance, and type 2 diabetes mellitus [12–15]. Adiponectin is
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also inversely correlated with body mass index (BMI) [9,16].
Genetic studies have investigated the association between
adiponectin-related genes and a wide variety of health outcomes,
including obesity, diabetes, cardio- and cerebrovascular disease
and dyslipidemia, nonalcoholic fatty liver disease, and a variety of
cancers including breast, colon and prostate [17].
Adiponectin acts through multiple pathways: it enhances
glucose utilization through AMPK phosphorylation; it antagonizes
TNF-alpha by negatively regulating its expression in various
tissues such as liver and macrophages; and it inhibits endothelial
NF-kappa-B signaling through a cAMP-dependent pathway
[1,2,4]. It may exert its anti-inflammatory effects by limiting
aberrant leukocyte-endothelial interactions and augmenting nitric
oxide availability [16]. Lower adiponectin levels have been
associated with inflammation, oxidative stress, and glucocorticoids,
and the link with insulin signaling suggests that adiponectin
secretion is highly affected by the insulin sensitivity of adipocytes
[1]. It has been postulated that adiponectin may be associated with
development of insulin resistance during critical illness [18].
Because of its links to inflammation and insulin sensitivity,
adiponectin has been investigated in a few critical care studies in
humans [16,18–21]. In general, these studies observed lower levels
of adiponectin at the onset of critical illness, with a rise during
recovery [16,18,19,21]. In one study of acute respiratory failure
patients, higher levels of adiponectin were associated with fewer
ventilator-free days and higher mortality [16]. This limited
literature on adiponectin in critical illness has not included studies
of genetic variations of the genes encoding adiponectin and its
receptors. Thus, the current study aims to investigate the
association between genetic variations in adiponectin-related
genes and the development of and survival in acute respiratory
distress syndrome (ARDS) in a large intensive care unit (ICU)
cohort.
Materials and Methods
The Human Subjects Committees (HSC) at the Massachusetts
General Hospital (MGH) and the Harvard School of Public
Health approved this study, and all participants or appropriate
surrogates provided informed consent and signed HSC-approved
consent forms.
Study Population and Design
This study is part of the ongoing Molecular Epidemiology of
ARDS Study of which study design and exclusion criteria have
been described in depth previously [22]. Adult ICU admissions to
MGH (Boston, MA) from January 1999 to March 2009, and at
Beth Israel-Deaconess Medical Center (BIDMC, Boston, MA)
from January 2007 to February 2009 were screened daily for
study-defined clinical risk factors for ARDS: pneumonia, sepsis or
septic shock, aspiration, massive transfusions, pulmonary contu-
sion or multiple fractures. Eligible patients were approached and
enrolled in the prospective cohort after consent was obtained.
Patients were followed daily until ICU discharge or death. They
were defined as having ARDS if they developed respiratory failure
requiring intubation and mechanical ventilation, and if they met
the North American-European Consensus Conference (AECC)
criteria for ARDS: arterial oxygen tension/fraction of inspired
oxygen ratio (PaO2/FiO2) of #200 mm Hg; bilateral infiltrates on
chest radiograph; and pulmonary arterial occlusion pressure
#18 mm Hg, or no clinical evidence of left atrial hypertension.
In the parent study, ARDS patients are cases, and patients with
ARDS risk factors who did not develop ARDS are controls. Day 0
of ARDS was defined as the day on which the case patient first
met all AECC criteria simultaneously. ARDS cases were followed
until Day 60 for all-cause mortality; controls were not followed for
mortality. The primary outcomes of the current substudy are (1)
development of ARDS in the at-risk cohort, and (2) death among
ARDS cases.
Genotyping
Genotyping of the parent cohort has been described in detail
previously [23,24]. Briefly, genomic DNA was extracted from
whole blood drawn during the first 48 hours of admission using
the Autopure LS robotic workstation (Gentra Systems, Minneap-
olis, MN) and DNA Purification Reagent Kits (Qiagen, Valencia,
CA). Genotyping was done at the Center for Applied Genomics,
Children’s Hospital of Philadelphia (Philadelphia, PA), using the
Illumina Human-CVD BeadChip (Illumina, San Diego, CA). The
Human-CVD BeadChip is a high-density genotyping platform
covering 48,742 markers across roughly 2100 genes associated
with cardiovascular, metabolic, and inflammatory pathways [25].
Genotyping personnel were blinded to ARDS case status, and
samples were processed according to Illumina’s protocols. Quality
control has also been described previously [23,24].
Forty-four single nucleotide polymorphisms (SNPs) on ADIPOQ,
ADIPOR1 and ADIPOR2 are included in the CVD BeadChip
platform. Of these, we hypothesized 9 SNPs a priori as functional
based on location, and as common with MAF.5% (Table 1).
These 9 SNPs were then analyzed for association with ARDS case
status, and mortality among ARDS cases.
Statistical Analysis
Demographic and clinical characteristics between various
groups were compared using chi-square tests for categorical
variables, and by Wilcoxon tests for continuous variables.
Correlations between genotypes and BMI or diabetes were tested
by calculating Spearman correlation coefficients. Diabetes status
Table 1. Selected Adiponectin and Receptor SNPs and
Genotype Frequencies in the Total Cohort.
Genotype, N (%)
Gene Polymorphism Location AA* AB BB MAF**
ADIPOQ rs266729 Promoter 1151 (56) 790
(38)
120 (6) 25.0%
ADIPOQ rs822387 59 of
Promoter
1699 (82) 349
(17)
17 (1) 9.3%
ADIPOQ rs864265 59 of
Promoter
1531 (74) 496
(24)
40 (2) 13.3%
ADIPOQ rs2082940 39 UTR 1562 (76) 453
(22)
49 (2) 13.4%
ADIPOQ rs16861194 Promoter 1738 (84) 496
(24)
40 (2) 8.3%
ADIPOR1 rs7539542 39 UTR 929 (45) 914
(44)
224
(11)
32.9%
ADIPOR2 rs1029629 59 of
Promoter
999 (48) 865
(42)
203
(10)
30.7%
ADIPOR2 rs1044471 39 UTR 536 (26) 1076
(52)
455
(22)
48.1%
ADIPOR2 rs16928751 Coding exon 1626 (79) 409
(20)
30 (1) 11.4%
*A denotes major allele; B denotes minor allele;
**MAF =minor allele frequency.
doi:10.1371/journal.pone.0089170.t001
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was abstracted from the medical record with any physician-
recorded documentation of type 1 or type 2 diabetes mellitus
defining positive diabetes status.
Logistic regression models were used to test the association of
SNP genotypes with ARDS case status. Cox proportional hazards
models were used to assess the association between SNP genotypes
and mortality. A multivariable model for each outcome without
genotypes was used to select significant predictors. A backward
elimination algorithm with p#0.2 for entry into the model was
used to test significance of the following clinically relevant
covariates: age, gender, Acute Physiology and Chronic Health
Evaluation (APACHE) III score, risk factor for ARDS (eg. sepsis,
pneumonia, trauma), massive transfusion (defined as requiring $8
units of red blood cells in 24 hours), and current history of
cirrhosis. Diabetes status and BMI were also included a priori given
the known biology of adiponectin. In multivariable analyses, the
APACHE III score was revised to exclude age and PaO2/FiO2 to
avoid collinearity [26]. BMI was considered as a 4-category
variable using the National Heart, Lung, and Blood Institute’s
cutoffs for underweight, normal weight, overweight, and obese
(,18.5, 18.5–24.9, 25–29.9, and $30 respectively) [27]. The
significant variables were then used in multivariable models that
included genotypes for each SNP. Given no preexisting knowledge
of mode of inheritance, additive, recessive, and dominant modes
were considered for all SNPs. Correction for multiple comparisons
was done using positive false discovery rate (FDR) statistics. The
FDR_q values were calculated using multivariable models with the
significant variables as above. All statistical analyses were
performed using SAS Version 9.3 (SAS Inc., Cary, North
Carolina).
Results
Patient population
From September 1999 to April 2009, consecutive ICU
admissions were screened for possible inclusion. In total, 4244
patients were eligible, of whom 2786 patients were successfully
consented, enrolled and followed for development of ARDS. Of
those enrolled, 387 had no or poor quality DNA samples, and an
additional 101 patients had genotyping call rates #95%. Also
excluded were 22 patients with incomplete clinical data, previous
enrollment, or previous history of ARDS, and 209 patients who
were not of European descent. Racial and ethnic categorization
was abstracted from hospital registration information with self-
report from patients or their surrogates. No genetic determination
of ancestry was attempted in this cohort. Thus, 2067 white patients
were successfully genotyped using the BeadChip at the loci of
interest. Of these, 567 patients developed ARDS.
Cases and control patients differed significantly in age,
APACHE III, and sepsis, septic shock, or direct pulmonary injury
as the risk factor ARDS (Table 2). Among ARDS cases, survivors
and nonsurvivors also differed significantly in age, APACHE III,
and septic shock or trauma as the risk factor ARDS (Table 3). BMI
was also significantly higher in ARDS cases than controls,
although BMI among survivors with ARDS was higher than in
nonsurvivors (Tables 2 and 3). Of note, the median for all groups
fell in the overweight range.
Genotype analysis
Genotype frequencies in this cohort for the 9 polymorphisms
from ADIPOQ, ADIPOR1 and ADIPOR2 are displayed in Table 1.
Our genotype frequencies are similar to publicly available
databases of European samples. Overall genotyping success rate
was 99.9% among the 2067 successfully genotyped with the chip.
Spearman correlation coefficients were calculated for genotype
at each SNP by BMI and by diabetes status. There were no
significant correlations between BMI and any SNP. There was a
statistically significant but weak positive correlation between
rs16861194 genotype (increasing number of variant alleles from
0 to 2) and diabetes status (r=0.060, p=0.0068).
Significant predictors of primary outcomes
As described above, multivariable logistic regression and Cox
proportional hazards regression were used to select relevant
covariates for inclusion in models with genotypes, with a
conservative p,0.2 for inclusion in the model. Significant
predictors for development of ARDS were: age [odds ratio (OR)
0.98, 95% confidence interval (CI) 0.98–0.99, p,0.0001]; BMI
(OR 1.20, 95% CI 1.08–1.33, p=0.0005); septic shock (OR 1.86,
95% CI 1.50–2.32, p,0.0001); direct pulmonary injury (OR 3.64,
95% CI 2.92–4.54, p,0.0001); diabetes (OR 0.56, 95% CI 0.44–
0.73, p,0.0001); and need for RBC transfusions (OR 1.57, 95%
CI 1.28–1.94, p,0.0001). Among ARDS cases, significant
predictors of mortality were: age [hazard ratio (HR) 1.03, 95%
CI 1.02–1.04, p,0.0001]; BMI (HR 0.89, 95% CI 0.79–1.01,
p=0.075); cirrhosis (HR 2.40, 95% CI 1.54–3.72, p,0.0001);
APACHE III (HR 1.02, 95% CI 1.02–1.03, p,0.0001); and
trauma (HR 0.21, 95% CI 0.067–0.67, p,0.0078). As mentioned,
BMI and diabetes status were chosen a priori to be included in all
models based on known biology of adiponectin.
Adiponectin-related genes and development of ARDS
The presence of the variant allele of rs1029629 on ADIPOR2
was significantly associated with development of ARDS in the
unadjusted model (OR 0.81, 95% CI 0.66–0.98, p=0.03). This
did not persist, however, after adjustment for significant covariates
(p=0.05), and adjustment for multiple testing (FDR_q=0.20). The
presence of the variant allele of rs16928571, also on ADIPOR2,
was associated with development of ARDS in both unadjusted and
multivariable models (OR 1.28, 95% CI 1.00–1.64, p = 0.05; OR
1.39, 95% CI 1.06–1.83, p = 0.02). When adjusting for multiple
comparisons, however, the result was not significant
(FDR_q=0.13). No other SNPs showed any significant association
with development of ARDS.
Adiponectin-related genes and mortality among ARDS
cases
Genotype frequencies in ARDS cases, including those in
survivors and nonsurvivors, are shown in Table 4. In unadjusted
analysis, homozygous variants of rs2082940 on ADIPOQ had a
highly significant increase in mortality (Table 5). This association
remained significant after adjusting for both relevant covariates
and for multiple comparisons. Hazard ratios for the other variables
included in the model are as follows: age (HR 1.03, 95% CI 1.02–
1.04, p,0.0001); APACHE III (HR 1.02, 95% CI 1.01–1.03,
p,0.0001); BMI (HR 0.87, 95% CI 0.75–1.00, p=0.05); cirrhosis
(HR 2.37, 95% CI 1.48–3.81, p=0.0004); diabetes (HR 1.19, 95%
CI 0.83–1.69, p=0.34); and trauma (HR 0.25, 95% CI 0.079–
0.79, p=0.018). No other SNPs were associated with mortality in
the ARDS cases. Results were similar when modeling survival
using logistic regression.
Among the 11 homozygous variants of rs2082940, 9 of the 10
nonsurivors died between 0 and 15 days after ARDS onset, and
one patient died after a prolonged hospital and ICU course, 57
days after onset of ARDS. The one survivor also had a protracted
hospital and ICU course. Among all 11 patients, there were no
major outliers in basic demographics or clinical features. Of note,
Adiponectin SNPs and ARDS Risk and Mortality
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however, 9 patients were overweight or obese, and 10 had sepsis or
septic shock, higher percentages than in our total cohort. The sole
survivor was also the only underweight patient of the 11, with an
ICU admission BMI of 18.0. An unadjusted Kaplan-Meier
survival plot is shown in Figure 1.
Discussion
This is the first study in the literature to report on variants of
ADIPOQ, ADIPOR1 and ADIPOR2 in association with mortality in
critically ill adults. Specifically, our results show a significant
increase in mortality for ARDS patients homozygous for the
rs2082940 variant. The rs2082940 polymorphism has also been
associated with increased risk of developing Type 2 diabetes
mellitus [28] and decreased risk of prostate cancer [29]. This SNP
is common (MAF 13.4%) and is located in the 39 UTR of
ADIPOQ. It has been shown in other studies to affect circulating
levels of adiponectin with the variant allele associated with
increased levels of adiponectin [28,29]. Thus, inference would
suggest that the higher mortality seen in our ARDS patients may
be associated with higher levels of adiponectin. Although we do
not have corresponding plasma adiponectin measurements in this
cohort, this inference would be consistent with previous human
studies showing lower adiponectin levels at ICU admission are
associated with improved survival [16,20].
Having said this, we know from previous genetic studies that
while adiponectin levels are highly heritable, SNPs in ADIPOQ
account for only a small percent of variability in circulating
adiponectin, ranging from ,2% to 8% across studies [30–32].
Thus, there are likely other important factors such as epigenetic
and environmental factors, interactions between loci, copy number
variations, and genetic polymorphisms outside of ADIPOQ [30,31].
For instance, the GEMS study identified a locus within CDH13
that was strongly associated with adiponectin levels [31]. This was
reiterated in a genome-wide association study (GWAS) of
adiponectin levels in Korean adults in which polymorphisms in
Table 2. Baseline Cohort Characteristics.
Total Cohort (n=2067) Controls (n =1500) Cases (n =567) P*
Age, mean 6 SD 61.5617.4 62.5617.1 58.8618.0 ,0.0001
Female gender, n (%) 785 (38) 577 (38) 208 (37) 0.46
BMI, median (IQR) 26.5 (8.0) 26.4 (7.8) 27.4 (9.0) 0.017
APACHE III score, mean 6 SD 60.4621.5 58.7620.9 65.3622.2 ,0.0001
Sepsis syndrome, n (%) 644 (31) 510 (34) 134 (24) ,0.0001
Pulmonary source 363 (56) 260 (51) 103 (77)
Septic shock, n (%) 1035 (50) 672 (45) 363 (64) ,0.0001
Pulmonary source 561 (54) 302 (45) 259 (71)
Trauma, n (%) 174 (8) 130 (9) 44 (8) 0.51
Massive transfusion, n (%) 215 (10) 161 (11) 54 (10) 0.42
Aspiration, n (%) 143 (7) 95 (6) 48 (9) 0.09
Direct pulmonary injury, n (%) 1153 (56) 730 (49) 423 (75) ,0.0001
*P-value reflects comparison between cases and controls.
SD = standard deviation; IQR = interquartile range; NS = not significant.
doi:10.1371/journal.pone.0089170.t002
Table 3. Cohort Characteristics of ARDS Cases by Mortality.
Survivors (n =355) Nonsurvivors (n =212) P*
Age, mean 6 SD 54.5618.1 66.1615.4 ,0.0001
Female gender, n (%) 124 (35) 84 (40) 0.26
BMI, median (IQR) 27.8 (9.7) 26.1 (6.8) 0.005
APACHE III score, mean 6 SD 58.1619.6 77.5620.9 ,0.0001
Sepsis syndrome, n (%) 88 (25) 46 (22) 0.40
Pulmonary source 65 (74) 38 (83)
Septic shock, n (%) 214 (60) 149 (70) 0.02
Pulmonary source 161 (75) 98 (66)
Trauma, n (%) 41 (12) 3 (1) ,0.0001
Massive transfusion, n (%) 35 (10) 19 (9) 0.72
Aspiration, n (%) 28 (8) 20 (9) 0.52
Direct pulmonary injury, n (%) 267 (75) 156 (74) 0.67
*P-value reflects comparison between survivors and nonsurvivors.
SD = standard deviation; IQR = interquartile range; NS = not significant.
doi:10.1371/journal.pone.0089170.t003
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the cadherin 13 gene (CDH13) made up 6 of the top 20 hits, and
ADIPOQ polymorphisms were not even represented among the top
20 [33]. This may also explain why we did not see any significant
results for rs822387, a polymorphism in the ADIPOQ promoter
that has been significantly associated with plasma adiponectin
levels in several studies [30,32]. This finding was not replicated,
however, in a whole genome analysis within the GEMS study [31],
or in a multiethnic meta-analysis [34]. Thus the functions of
ADIPOQ clearly go beyond just expression of adiponectin.
There have also been several previous genome-wide association
studies that have identified expression quantitative trait loci
(eQTLs) for plasma adiponectin [30,31,34]. These include
rs6810075, rs17300539/rs822387, rs17366568, and rs6773957.
Using the SNP Annotation and Proxy Search database (SNAP,
http://www.broadinstitute.org/mpg/snap/), pairwise linkage
analysis reveals that both rs6773957 and rs17366568 are in
complete linkage disequilibrium with rs2082940 (D9=1.0) [35].
However, r2 for both eQTLs is low (0.19 and 0.02 respectively),
likely reflecting differences in allele (and thus haplotype) frequen-
cies. Still, the high D9 suggests a strong coinheritance of rs2082940
with these eQTLs. In pairwise analysis with the remaining eQTLs
and rs2082940, linkage disequilibrium was extremely low
(D9#0.007).
Since adiponectin is anti-inflammatory in nature, it is somewhat
unintuitive that lower adiponectin levels on ICU admission would
be associated with better survival, but this has been show in at least
two studies [16,20]. One hypothesis is that lower adiponectin
acutely allows the proinflammatory response to predominate, but
that as critical illness progresses into a more subacute or chronic
phase, adiponectin rises or normalizes as the anti-inflammatory
response becomes more important [36], and this biphasic response
has been described by several authors [16,18,21,36]. It is later in
critical illness when production of anti-inflammatory cytokines
such as IL-10 increases, and macrophages shift to their M2 form
which has local anti-inflammatory and insulin-sensitizing features
[36]. This biphasic theory of adiponectin in critical illness may
partly explain why animal models have shown hypoadiponectine-
mia to be associated with worsened survival in sepsis and acute
lung injury [6,7]. Although not entirely analogous to human
studies, these studies used adiponectin knockout mice, and thus the
animals would not have the ability to increase adiponectin levels
during the evolution of their critical illness.
Of the 10 ARDS case patients who were homozygous variant at
rs2082940, only one died outside the first 2 weeks after onset of
ARDS. This would suggest that patients generally died of
multiorgan failure, overwhelming infection, and/or severe hyp-
oxemic respiratory failure. Even the lone survivor had a prolonged
hospital course lasting nearly 2 months from ARDS onset, and
that case was the only underweight patient among the homozy-
gous recessive group. The only salient features of nonsurvivors, as
noted above, were a high percentage of BMI$25 and sepsis/septic
shock. Overall, this would support the hypothesis that blunting of
the pro-inflammatory response in acute critical illness is detri-
mental, if indeed adiponectin levels are increased in these patients.
In one respect, we would not necessarily expect adiponectin to
act differently in ARDS patients than in other critically ill subjects
with acute inflammation of various etiologies. ARDS respresents
an intense inflammatory syndrome localized in the lung but with
Table 4. Genotype Frequencies in ARDS Cases.
ARDS Cases, N (%) Survivors N (%) Nonsurvivors N (%)
AA* AB BB AA AB BB AA AB BB
rs266729 312 (55) 220 (39) 33 (6) 192 (54) 138 (39) 25 (7) 120 (57) 82 (39) 8 (4)
rs822387 464 (82) 99 (17) 4 (1) 292 (82) 61 (17) 2 (1) 172 (81) 38 (18) 2 (1)
rs864265 422 (74) 137 (24) 8 (2) 267 (75) 81 (23) 7 (2) 155 (73) 56 (26) 1 (1)
rs2082940 435 (77) 120 (21) 11 (2) 285 (80) 69 (20) 1 (,1) 150 (71) 51 (24) 10 (5)
rs16861194 477 (84) 88 (16) 2 (,1) 302 (85) 51 (14) 2 (1) 175 (83) 37 (17) 0 (0)
rs7539542 247 (44) 260 (46) 60 (11) 159 (45) 161 (45) 35 (10) 88 (42) 99 (47) 25 (12)
rs1029629 252 (44) 257 (45) 58 (10) 159 (45) 157 (44) 39 (11) 93 (44) 100 (47) 19 (9)
rs1044471 157 (28) 276 (49) 134 (24) 102 (29) 167 (47) 86 (24) 55 (26) 109 (51) 48 (23)
rs16928751 463 (82) 95 (17) 9 (1) 286 (80) 66 (19) 3 (1) 177 (83) 29 (14) 6 (3)
*A denotes major allele; B denotes minor allele.
doi:10.1371/journal.pone.0089170.t004
Table 5. Cox Proportional Hazards Models of Mortality by
Genotype in ARDS Cases (n = 566).6
Crude HR
(95% CI) P
Adjusted
HR*(95% CI) P FDR_q
ADIPOQ
rs266729 0.60 (0.30–1.21) 0.16 0.71 (0.34–1.45) 0.34 0.37
rs822387 1.07 (0.27–4.30) 0.93 1.95 (0.48–7.91) 0.35 0.37
rs864265 0.27 (0.038–
1.92)
0.19 0.23 (0.032–1.64) 0.14 0.27
rs2082940 4.09 (2.16–7.74) ,0.0001 2.61 (1.36–5.00) 0.004 0.02
rs16861194 —** 0.97 —** 0.98 0.68
ADIPOR1
rs7539542 1.18 (0.78–1.79) 0.44 1.46 (0.94–2.27) 0.09 0.27
ADIPOR2
rs1029629 0.87 (0.54–1.39) 0.56 0.96 (0.59–1.57) 0.87 0.68
rs1044471 0.98 (0.71–1.36) 0.91 0.92 (0.66–1.29) 0.64 0.57
rs16928751 2.12 (0.94–4.78) 0.07 1.78 (0.77–4.09) 0.17 0.27
6Models shown represent recessive inheritance pattern.
*Also included in the model: age, BMI, APACHE, trauma, cirrhosis, diabetes.
**HR could not be calculated because only 0.7% of subjects genotyped at this
locus had the homozygous variant genotype.
HR = hazard ratio; CI = confidence interval; FDR_q= false discovery rate q-value.
doi:10.1371/journal.pone.0089170.t005
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systemic effects. Sepsis and septic shock also represent intense
systemic inflammation, and such patients make up a large subset of
our cohort developing ARDS. The observation that plasma
cortisol and plasma adiponectin are highly correlated in healthy
subjects may support that adiponectin is a marker for severity of
illness [19], although we adjusted our results for APACHE III
scores. In another respect, however, adiponectin may act
differently in that obesity has been implicated as a risk factor for
developing acute lung injury [37–39], yet diabetes has been well-
described as a protective factor against developing ARDS [40].
Given adiponectin’s link to both of these risk factors with quite
opposite effects on ARDS susceptibility, there has been specific
interest in adiponectin in ARDS [7].
We found no relationship between SNPs and BMI, and weak
correlation between diabetes status and rs16861194. BMI is an
imperfect measure in the ICU where weight can reflect the effects
of acute illness or of fluid resuscitation. And although many studies
have shown an inverse correlation between BMI and adiponectin,
plasma levels are certainly affected by many genetic and
nongenetic factors, and we examined only a small number of
SNPs. BMI has also been associated with an increased risk of
ARDS in a weight-dependent manner as mentioned above, [37]
and BMI was significant in our multivariable models of outcomes.
We acknowledge limitations in this study. No measurements of
adipokine levels are available for this cohort, and thus we cannot
specifically link a genotype to a phenotypic correlate. We were also
not able to control for insulin dosing or serum glucose levels
throughout the ICU stay. This study is an exploratory analysis of
available SNPs, several without known function. However, the
most significant finding was in a SNP that has been studied, as
above, although there were few homozygous recessive patients at
this locus.
There are many strengths in this study. Perhaps most
importantly, this is a large, prospective, well-characterized cohort
with minimal misclassification. DNA quality was excellent with
high genotyping success rates. This cohort also has a high
percentage of patients with sepsis and septic shock, and along with
ARDS itself, the cohort thus represents well the inflammatory
sequelae of severe infection and critical illness. We controlled for
diabetes and weight (BMI) as these are known to be associated
with variations in adiponectin levels. This study also represents an
addition to limited existing literature on the role of these genes and
their polymorphisms in the critically ill.
Conclusion
A common and potentially functional polymorphism in
ADIPOQ may impact survival in ARDS. In general, adipokine-
related genes may be relevant in survival from critical illness,
possibly via insulin resistance and endothelial reactivity and
inflammatory pathways.
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